Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$149.40 USD
-1.82 (-1.20%)
Updated May 17, 2024 04:00 PM ET
After-Market: $149.43 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/1/24 |
---|---|
Current Quarter | -0.79 |
EPS Last Quarter | -0.16 |
Last EPS Surprise | 78.67% |
ABR | 1.84 |
Earnings ESP
|
2.46% |
---|---|
Current Year | -1.97 |
Next Year | -0.38 |
EPS (TTM) | -2.32 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 448.45M | 459.31M | 1.86B | 2.20B |
# of Estimates | 11 | 11 | 12 | 12 |
High Estimate | 489.09M | 495.50M | 1.94B | 2.53B |
Low Estimate | 430.41M | 443.00M | 1.78B | 1.88B |
Year ago Sales | 318.75M | 750.53M | 1.83B | 1.86B |
Year over Year Growth Est. | 40.69% | -38.80% | 1.76% | 18.42% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.79 | -0.72 | -1.97 | -0.38 |
# of Estimates | 8 | 8 | 8 | 9 |
Most Recent Consensus | -0.76 | -0.48 | -1.69 | 0.80 |
High Estimate | -0.38 | -0.41 | -1.07 | 1.72 |
Low Estimate | -1.26 | -1.29 | -2.79 | -1.99 |
Year ago EPS | -2.21 | 1.15 | -3.52 | -1.97 |
Year over Year Growth Est. | 64.25% | -162.61% | 44.03% | 81.12% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 3 | 2 | 5 | 2 |
Up Last 60 Days | 4 | 3 | 6 | 3 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 4 | 5 | 1 | 6 |
Down Last 60 Days | 4 | 5 | 1 | 6 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.79 | -0.72 | -1.97 | -0.38 |
7 Days Ago | -0.79 | -0.72 | -1.97 | -0.38 |
30 Days Ago | -0.76 | -0.76 | -2.43 | -0.44 |
60 Days Ago | -0.77 | -0.79 | -2.53 | -0.60 |
90 Days Ago | -0.95 | -1.00 | -3.27 | -1.01 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.77 | -0.72 | -1.82 | -0.33 |
Zacks Consensus Estimate | -0.79 | -0.72 | -1.97 | -0.38 |
Earnings ESP | 2.46% | -0.92% | 7.87% | 12.13% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.16 | -1.10 | 1.15 | -2.21 | NA |
Estimate | -0.75 | -1.20 | -1.61 | -1.72 | NA |
Difference | 0.59 | 0.10 | 2.76 | -0.49 | 0.74 |
Surprise | 78.67% | 8.33% | 171.43% | -28.49% | 57.49% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more